Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations
06 January 2022 - 11:00PM
Business Wire
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a
clinical-stage biopharmaceutical company developing novel solutions
for people suffering from acute cannabinoid intoxication and
substance abuse, announced today that it has appointed Scott L.
Anderson as Head of Investor Relations and Public Relations,
effective immediately.
In this position, Mr. Anderson will report directly to Rex
Merchant, Anebulo’s Chief Financial Officer. Mr. Anderson will be
responsible for Anebulo’s global investor relations and public
relations programs. He serves as the primary spokesperson and point
of contact with the analyst and investment community and is also
responsible for the timely dissemination of information and data to
these important stakeholders.
Mr. Anderson will build on Anebulo’s current investor relations
and public relations programs to grow and diversify the Company's
shareholder base as well as to enhance its communications with
shareholders and other stakeholders. Scott will work closely with
the management team to further develop the company's internal and
external communications with a focus on strategy, branding, social
media presence and investor communications.
Mr. Anderson brings more than 20 years of public company
experience to Anebulo, having served in various investor relations
and corporate communications roles at such companies as Qualcomm,
Qorvo (formerly RF Micro Devices), Actavis plc (formerly Watson
Pharmaceuticals), and O2Micro International Limited.
Commenting on the appointment, Dr. Daniel Schneeberger, CEO,
said: "We are extremely pleased to welcome Scott to the Anebulo
Team. His experience and insights make him ideally suited to
support the continued development of our investor relations program
and goals. Based on our plans to report topline results from our
ongoing Phase 2 trial in the first half of the year, it is a great
time to bolster our investor relations program and ensure best
practices to drive shareholder value."
Mr. Anderson added, "I'm delighted to be joining Anebulo at this
unique and exciting time. I look forward to assisting Anebulo to
communicate the Company's strategic initiatives and performance
drivers to the financial community and its key stakeholders."
Mr. Anderson earned a B.A. degree in Communication Arts &
Sciences from the Annenberg School for Communication and Journalism
at the University of Southern California.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing novel solutions for people
suffering from acute cannabinoid intoxication and substance abuse.
Its lead product candidate, ANEB-001, is intended to reverse the
negative effects of acute cannabinoid intoxication within one hour
of administration. ANEB-001 is a competitive antagonist at the
human cannabinoid receptor type 1 (CB1) with good oral
bioavailability and brain penetration (rat brain:plasma ratio of
approximately 1.5). Clinical trials completed to date have shown
that ANEB-001 is rapidly absorbed, well tolerated, and may lead to
weight loss, an effect that is consistent with CB1 antagonism in
the central nervous system. For further information about Anebulo,
please visit www.anebulo.com.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements, along with terms such as
“anticipate,” “expect,” “intend,” “may,” “will,” “should” and other
comparable terms, involve risks and uncertainties because they
relate to events and depend on circumstances that will occur in the
future. Those statements include statements regarding the intent,
belief or current expectations of Anebulo Pharmaceuticals and
members of its management, as well as the assumptions on which such
statements are based. Prospective investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, including risks
attendant to developing, testing and commercializing the company’s
product candidates, and those described in Anebulo Pharmaceutical’s
most recent annual report on Form 10-K and in other periodic
reports filed with the SEC, and that actual results may differ
materially from those contemplated by such forward-looking
statements. Except as required by federal securities law, Anebulo
Pharmaceuticals undertakes no obligation to update or revise
forward-looking statements to reflect changed conditions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220106005069/en/
Anebulo Pharmaceuticals, Inc. Scott Anderson Head of
Investor Relations and Public Relations (858) 229-7063
scott@anebulo.com
Rex Merchant Chief Financial Officer (512) 598-0931
IR@anebulo.com
Anebulo Pharmaceuticals (NASDAQ:ANEB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anebulo Pharmaceuticals (NASDAQ:ANEB)
Historical Stock Chart
From Apr 2023 to Apr 2024